Drug Profile

Vutiglabridin - Glaceum

Alternative Names: HSG-4112

Latest Information Update: 17 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Glaceum
Class Hepatoprotectants; Obesity therapies; Phenols; Pyrans; Small molecules
Mechanism of Action Inflammation mediator inhibitors; Metabolism stimulants; Triglyceride modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Obesity; Parkinson's disease
No development reported Non-alcoholic steatohepatitis

Most Recent Events

25 Feb 2025 Glaceum plans a phase II trial in Osteoarthritis (PO) in June 2025 (NCT06845553)
28 Dec 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in South Korea (PO, Tablet)
12 Apr 2024 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com